Spots Global Cancer Trial Database for Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Official Title: A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
Study ID: NCT02932280
Interventions
Study Description
Brief Summary: The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Detailed Description:
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Phoenix Children'S Hospital, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California, United States
Arnold Palmer Hospital for Children, Orlando, Florida, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Pennsylvania State Hershey Children's Hospital, Hershey, Pennsylvania, United States
University of Texas, San Antonio, Texas, United States
Huntsman Cancer Institue, Salt Lake City, Utah, United States
Alberta Children'S Hospital, Calgary, Alberta, Canada
Contact Details
Name: Tanya Trippett, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
